Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 961

Sort by

Sort Order Select

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Jordan Gauthier, Alexandre V. Hirayama, Janaki Purushe, Kevin A. Hay, James Lymp, Daniel H. Li, Cecilia C. S. Yeung, Alyssa Sheih, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Tinh-Doan Phi, Rachel N. Steinmetz, Mazyar Shadman, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2020) 135 (19): 1650–1660.

https://doi.org/10.1182/blood.2019002936

Published: 2020

Includes: Supplemental data

Journal Articles

Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo

Yu-Lin Su, Xiuli Wang, Mati Mann, Tomasz P. Adamus, Dongfang Wang, Dayson F. Moreira, Zhuoran Zhang, Ching Ouyang, Xin He, Bin Zhang, Piotr M. Swiderski, Stephen J. Forman, David Baltimore, Ling Li, Guido Marcucci, Mark P. Boldin, Marcin Kortylewski

Blood (2020) 135 (3): 167–180.

https://doi.org/10.1182/blood.2019002045

Published: 2020

Includes: Supplemental data

Journal Articles

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner, Francesco Ceppi, Julie Rivers, Colleen Annesley, Corinne Summers, Agne Taraseviciute, Juliane Gust, Kasey J. Leger, Katherine Tarlock, Todd M. Cooper, Olivia C. Finney, Hannah Brakke, Daniel H. Li, Julie R. Park, Michael C. Jensen

Blood (2019) 134 (24): 2149–2158.

https://doi.org/10.1182/blood.2019001463

Published: 2019

Includes: Supplemental data

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4435.

https://doi.org/10.1182/blood-2019-126104

Published: 2019

Journal Articles

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

Veronica Asnaghi, MD, Maria Ballabio, MD, Philippe Jacqmin, Kathy de Graaf, Cristina De Min, MD

Blood (2019) 134 (Supplement_1): 2333.

https://doi.org/10.1182/blood-2019-123995

Published: 2019

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

Clinical Characteristics and Outcome of Biphenotypic Acute Leukemia: 10 Cases Report and Literature Review

Jifeng Yu, MD, Yingmei Li, MD, Haizhou Xing, Hui Sun, Dingming Wan, MD, Yanfang Liu, Xinsheng Xie, MD, Chong Wang, Ling Sun, MD PhD, Kai Sun, MD, Zhongxing Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 5207.

https://doi.org/10.1182/blood-2019-127580

Published: 2019

Journal Articles

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Elise A. Chong, MD, Meredith I LaRose, MD, Steven M. Bair, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elizabeth Weber, BSN, RN, Chase Walling, BS, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 1606.

https://doi.org/10.1182/blood-2019-131482

Published: 2019

Journal Articles

Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1603.

https://doi.org/10.1182/blood-2019-125162

Published: 2019

Journal Articles

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 1367.

https://doi.org/10.1182/blood-2019-128044

Published: 2019

Journal Articles

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1609.

https://doi.org/10.1182/blood-2019-131499

Published: 2019

Journal Articles

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Matthew Frigault, MD MSc, Megan Cartwright, PhD, Krista Marcello, BA, Timothy A Quill, PhD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Shilpa Paul, PharmD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 2199.

https://doi.org/10.1182/blood-2019-131533

Published: 2019

Journal Articles

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics

Florent Malard, MD PhD, Faezeh Legrand, MD, Jérôme Cornillon, MD, Amandine Le Bourgeois, MD, Jean-Baptiste Mear, MD, Deborah Desmier, MD, Emilie Plantamura, PhD PharmD, Ronald Carter, MD MSc, MPH, Thierry Lamy De La Chapelle, MD PhD, Patrice Chevallier, MD, Denis Guyotat, MD PhD, Didier Blaise, MD PhD, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 1993.

https://doi.org/10.1182/blood-2019-125540

Published: 2019

Journal Articles

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A Sallman, MD, Jason B. Brayer, PhDMD, Xavier Poire, Violaine Havelange, Ahmad Awada, MD PhD, Philippe Lewalle, Kunle Odunsi, MD, Eunice S. Wang, MD, Caroline Lonez, PhD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Nathalie Braun, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3826.

https://doi.org/10.1182/blood-2019-128020

Published: 2019

Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3887.

https://doi.org/10.1182/blood-2019-128506

Published: 2019

Journal Articles

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nassim Djebli, PhD PharmD, Felix Jaminion, MSc, Johann Laurent, MSc, Francois Mercier, PhD, Nicole A Kratochwil, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Tom Moore, MBChB, Martin Weisser, MD, Peter N Morcos, PharmD

Blood (2019) 134 (Supplement_1): 3799.

https://doi.org/10.1182/blood-2019-123712

Published: 2019

Journal Articles

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab

Blood (2019) 134 (Supplement_1): 3809.

https://doi.org/10.1182/blood-2019-125466

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

DARTs point the way forward in AML

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

Clinical Characteristics and Outcome of Biphenotypic Acute Leukemia: 10 Cases Report and Literature Review

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only